Increasing numbers of HIV-1 infected patients have a history of multiple treatment failures [1–3]. Resistance mutations in key genes may confer impaired fitness and reduced replicative capacity [4–6], and viruses harbouring multiple resistance mutations would have a substantially reduced transmission capacity . Despite this, sexual transmission of such viral variants occurs [8–10]. In France, the frequency of transmitted resistant strains at the time of primary HIV infection (PHI) is stable and reaches 12% . It could be expected that resistant HIV-1 strains acquired at the time of PHI would not persist over time in a drug-free environment, being overwhelmed by fitter wild-type strains, as seen during chronic disease in patients who discontinue a failing regimen [12,13]. However, there is recent evidence that detectable resistance may persist in plasma over a long time after PHI without drug-selective pressure [14–18]. The clinical implications are of serious concern since multidrug resistance (MDR) can result in treatment failure and clinical progression of PHI patients with MDR virus [16,19,20], especially within the first year following PHI . Our objective was to characterize the early establishment of the viral cellular reservoir, and to analyse the temporal evolution of resistance mutations acquired at PHI not only in circulating recently produced HIV particles, but also in strains stored in the cellular reservoir, in treated and in untreated patients. Therefore, we compared resistance mutational pattern between HIV RNA and HIV DNA sampled at the time of PHI in patients enrolled in a national cohort of primary HIV-1 infection in France. Then, we monitored HIV resistance-associated mutations present in plasma HIV RNA, and in HIV DNA in peripheral blood mononuclear cells (PBMC), in a subset of patients, in the absence or in the presence of early HAART.
Patients and methods
Our study comprised patients presenting with PHI, enrolled in the multicentre prospective French Primo Cohort (ANRS CO 06) [19,22–24]. The ethics committee of Cochin Hospital approved the study and all patients gave their written informed consent. From 1996 to December 2004, 518 PHI patients were enrolled in the cohort, with a median HIV RNA of 5.05 log10 copies/ml (range, 2.3–8.33 log10) and a median CD4 cell count of 521/μl (range, 69–1542/μl) at inclusion. This observational cohort does not impose guidelines for systematic treatment of patients presenting with PHI, the decision of initiating HAART or not relying on the primary care physician in each clinical setting. Seventy percent (364/518) of enrolled patients were started on antiretroviral therapy at confirmation of diagnosis of PHI, with a significant decrease from 92% in 1996 to 56% in 2001 (P < 10−6) , and to 33% in 2004 .
For all patients enrolled in the Primo Cohort, plasma samples were collected at inclusion and stored for retrospective genotypic resistance testing for epidemiological purposes . Therefore, when initiated during PHI, HAART began before the results of genotypic resistance testing were available.
Primary HIV-infection was identified as previously described . Briefly, primary HIV-infection was assessed by: (i) a negative or indeterminate HIV ELISA associated with a positive antigenemia or plasma HIV RNA; (ii) a western blot profile compatible with ongoing seroconversion (incomplete western blot with absence of antibodies to Pol proteins); or (iii) an initially negative test for HIV antibody followed by positive HIV serology within 6 months.
Patients enrolled in the Primo Cohort were selected for the present study if: (i) they harboured plasma HIV-1 strains resistant to at least one antiretroviral drug at time of PHI; and (ii) they were not co-included in structured treatment interruption trials  or in immune-based therapy trials [28,29]. Longitudinal monitoring of resistance mutational pattern was performed in a subset of patients with a minimum of 2 years of follow up if stored blood plasma and PBMC samples were available. Genotypic resistance tests were performed retrospectively on paired stored samples of plasma and PBMC collected at baseline, at month 6 (M6), M12, M24 and then every 12 months when available.
Quantification of HIV RNA in blood plasma
HIV RNA was quantified by using the Cobas Amplicor HIV-1 Monitor 1.5 assay kit (Roche Diagnostics, Meylan, France) according to the manufacturer's instructions: the detection limit was 400 copies/ml.
Quantification of HIV DNA in PBMC
PBMC were isolated from fresh whole blood by centrifugation on a one-layer Ficoll Hypaque gradient. PBMC were washed three times in RPMI medium, then counted and kept as dry pellets at −80°C. Four hundred microliters of lysis buffer from the Whole Blood Specimen Preparation Kit (Roche SA, Meylan, France) were added to the cellular fractions. PBMC HIV DNA was extracted and quantified by real-time PCR. The real-time PCR targets a conserved consensus region in the long terminal repeat (LTR) region of the HIV-1 major group. The sequences of the forward and reverse primers, and thermocycling conditions have been published elsewhere . This method detects all forms of intracellular HIV DNA: unintegrated and integrated linear DNA, 1-LTR and 2-LTR circles [31,32]. Results were expressed as log10 number of HIV DNA copies per 106 PBMC.
Genotypic resistance tests
The HIV-1 reverse transcriptase (RT) and protease genes were amplified from cell-associated proviral DNA and from plasma HIV RNA by a first-round PCR followed by nested PCR using published primers . For HIV DNA, 1 μg DNA extracted from total PBMC was amplified by PCR. PCR final products were visualized on gels then purified using the QIAquick PCR Purification HIV kit (Qiagen, Valencia, California, USA). After purification, PCR products were sequenced using the fluorescent dideoxy-terminator method (Big Dye Terminator kit, Applied Biosystem, Perkin Elmer, Foster City, California, USA) on an Applied Biosystem 377 automated DNA sequencer (ABI/PE, Foster City, California, USA). Sequences were aligned using Sequence Navigator software. The amino acids at codons associated with resistance to nucleoside analogue reverse transcriptase inhibitors (NRTI), non-nucleoside analogue reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PI) were identified according to the 2004 International AIDS Society list (www.iasusa.org). HIV drug resistance was defined according to the 2004 HIV-1 genotypic resistance interpretation algorithm of the French National Agency for Research on AIDS (ANRS) (www.hivfrenchresistance.org).
Clones of HIV DNA
To characterize the quasi-species present in the cellular reservoir at baseline, i.e., early after PHI, HIV DNA protease gene PCR products from two patients' baseline PBMC samples were cloned into the pCR®Topo 2-1 plasmid (TOPO TA Cloning kits, Invitrogen BV, the Netherlands) as recommended by the manufacturer. DNA was purified with the Mini-Prep kit (Qiagen) and then sequenced as described above.
All sequences of HIV RNA and HIV DNA RT gene from the 10 patients for whom longitudinal follow up was available, and HIV DNA protease gene clones from two patients were aligned with Clustal W 1.6 software. In addition, sequences of the HIV RT gene of 10 subjects from the surronding community, enrolled in the Cohort during the same period, without transmitted drug resistance, were added. Pairwise evolutionary distances were estimated with DNADist, using Kimura's two-parameter method, then the phylogenetic trees were constructed by a neighbour joining method (neighbour program implemented in the Phylip package) . The reliability of each tree topology was estimated from 1000 bootstrap replicates .
Patients' characteristics at baseline
Forty-four patients (80% men) enrolled in the Primo cohort harboured an HIV-1 strain that was resistant to at least one antiretroviral-drug at the time of PHI, and were eligible for the present study. Median time between HIV infection and inclusion in the cohort was 46 days (range, 24–183 days). At the time of PHI, median CD4 cell count, plasma HIV RNA and PBMC HIV DNA loads were 507/μl (range, 83–1509/μl), 4.61 log10 copies/ml (range, 1.77–6.73 log10 copies/ml) and 3.21 log10 copies/106 cells (range, 1.70–4.41 log10 copies/106 cells) respectively. Resistance to NRTI, NNRTI, and PI was detected in plasma HIV RNA in 27/44 patients, 13/44 patients and 23/44 patients, respectively. Eleven and five patients harboured plasma HIV-1 strains with resistance to two and all three antiretroviral drug classes, respectively. Mutation M184V in the RT gene was detected in HIV RNA of 11/44 patients.
For the 44 patients, all resistance mutations detected at the time of PHI in plasma HIV RNA were also detected in HIV DNA extracted from paired PBMC samples (Fig. 1a and b). However, in patient 7, a mixture of amino acid residue M/I was detected at position 184 of the RT gene in PBMC HIV DNA, whereas only wild-type amino acid was detected at that specific position in HIV RNA extracted from paired plasma sample.
Baseline characteristics of the subset of 10 patients with longitudinal follow up
Those 10 patients were included in the Primo cohort between March 1999 and February 2002. Median time between HIV infection and inclusion in the cohort was 57 days (range, 28–183 days), and median time between HIV diagnosis and inclusion was 32 days (range, 12–150 days). All patients presented with mild to severe symptomatic PHI. Baseline median plasma HIV RNA, PBMC HIV DNA and CD4 cell count values were 4.30 log10copies/ml (range, 2.4–5.7 log10copies/ml), 2.92 log10 copies/106 PBMC (range, 1.8–3.7 log10 copies/106 PBMC) and 562/μl (range, 300–1508/μl), respectively. For each patient, we found that baseline genotypic resistance profile was identical in HIV RNA from blood plasma and in HIV DNA from PBMC. Longitudinal monitoring of viral genotype in HIV RNA and PBMC HIV DNA was performed on samples from all ten patients for a median follow up period of 24 months (range, 24–48 months).
Longitudinal assessment of viral genotype in the five untreated patients (patients 32–36)
Results are shown in Table 1. At baseline, median HIV RNA load was 3.73 log10 copies/ml (range, 2.45–4.62 log10 copies/ml), median PBMC HIV DNA load was 2.4 log10 copies/106 PBMC (range, 1.84–3.65 log10 copies/106), and median CD4 cell count was 605/μl (range, 585–1508/μl). At inclusion, three patients were identified with resistance to one antiretroviral class (36, NNRTI; 34 and 35; NRTI), one patient to two antiretroviral classes (33; NRTI and PI) and one patient (32) to three antiretroviral classes (Table 1). The final evaluation took place at M24 for patients 32, 34, 35, 36, and M48 for patient 33.
As shown in Table 1, all HIV resistance-associated mutations persisted in HIV RNA and in PBMC HIV DNA throughout the follow up, except for mutation 215Y with a stepwise back-mutation at that specific position, leading to a shift to 215C in plasma HIV RNA at M12 then in PBMC HIV DNA at M24 for patient 35, and in both plasma HIV RNA and PBMC HIV DNA at M24 in patients 32 and 33.
Finally, none of the untreated patients experienced rapid progression to AIDS during follow up.
Longitudinal assessment of viral genotype in the five patients on HAART (patients 37–41)
Results are presented in Table 2. At baseline, median HIV RNA was 4.33 log10 copies/ml (range, 4.06–5.11 log10 copies/ml), PBMC HIV DNA load was 2.98 log10 copies/106 PBMC (range, 2.89–3.72 log10 copies/106 PBMC), and median CD4 cell count was 461/μl (range, 300–593/μl). One patient was identified with resistance to one antiretroviral class (41, PI), two with resistance to two antiretroviral classes (39 and 40, NRTI and PI), and two (37, 38) with resistance to three antiretroviral classes (Table 2). Patients were started on HAART as soon as PHI was confirmed, that is on the day of inclusion in the Primo Cohort (D0). At baseline (D0), HAART consisted of two NRTI in association with efavirenz (n = 3) or with nelfinavir (n = 2). The final evaluation took place at M24 in patients 37 and 39, M36 in patients 40 and 41, and M48 in patient 38.
Patient 37 was started on zidovudine, lamivudine and efavirenz, while he harboured an HIV strain with mutations associated with resistance to both zidovudine (215F) and efavirenz (181C). Patient 38 who was receiving zidovudine, lamivudine and nelfinavir, was infected with an HIV mutated strain that harboured mutations associated with resistance to all three drugs (zidovudine: 67N/70R/151M/215V/219Q; lamivudine: 184V, nelfinavir: 36I/46I/82A). These two patients achieved sustained undetectable plasma HIV RNA beginning from M6, with retention of all archived drug resistance-associated mutations in PBMC HIV DNA throughout median 24 months of follow up (Table 2).
In the other three patients, viral replication persisted under drug-selective pressure, with accumulation of additional drug-resistance mutations selected by the ongoing treatment in two out of three patients (40, +70R, 101E, 190S; 41, +184V). These additional mutations were first detected in plasma (M6), then in PBMC HIV DNA at M24 for patient 40 and M36 for patient 41.
Patient 40, whose virus bore mutation 184V at time of PHI, discontinued his failing regimen (zidovudine, lamivudine and efavirenz) at M18. A shift to wild-type amino acid residue occurred at positions 70 and 184 at M24 in plasma HIV RNA, but with a retention of both resistance mutations in PBMC HIV DNA.
Phylogenetic analysis of HIV RT gene
To analyse the temporal evolution of HIV RT gene in plasma and in PBMC, a total of 70 sequences of HIV RNA and HIV DNA RT gene from study patients were analysed, along with 10 RT sequences of patients from the surrounding community presenting with PHI without transmitted drug resistance (Fig. 2). All sequences showed the expected patient-specific clustering. Two features were evidenced. For a given patient, HIV RNA and HIV DNA sequences clustered together at the same time of sampling, with high bootstrap values (32–34). Conversely for another patient (35), HIV RNA and HIV DNA sequences from paired samples at D0, M6 and M12 did not cluster together at a given time-point.
Based on pairwise evolutionary distances, the temporal analysis of RT sequences showed limited evolution between the first and the last available sequence for each patient. Genetic evolution was extremely limited for untreated patients, with less than 1% variability in HIV RNA and ranging from 0.2 to 1.6% in HIV DNA (Table 3), most likely reflecting an absence of selective (e.g., drug) pressure. Genetic evolution was a little higher in treated patients 40 and 41 who failed their first-line empirical regimen, with a variability ranging from 1.5 to 2.8% in HIV RNA and from 0.5 to 3% in HIV DNA (Table 2).
Phylogenetic analysis of HIV DNA protease gene clones from baseline PBMC
We analyzed the sequences of HIV DNA protease gene clones from PBMC samples at baseline in two patients (40,41) (Fig. 3). In both cases, the most striking finding was the high homogeneity of the quasispecies integrated in PBMC at an early time-point during PHI. Based on pairwise evolutionary distances, the intravariability between quasispecies was 0.49% (range, 0–1) in patient 40 and 0.50% (range, 0–1.4) in patient 41.
Further analysis of resistance mutations strengthened the homogeneity of strains integrated in PBMC early during PHI, showing exclusively homogenous and resistant quasispecies, with all quasispecies harbouring the same mutational pattern for each patient. Finally, no wild-type quasispecies were detected in PBMC sampled at baseline.
The presence of HIV drug-resistant variants poses significant challenge to effective therapeutic intervention at any stage of infection, including PHI. We not only confirm that acquired resistant viruses establish themselves as the dominant viral population at primary infection, but also, focusing on PBMC HIV DNA, we show that these resistant variants are also present in the cellular reservoir in all 44 patients at this early time-point in HIV infection. Moreover, resistance mutations remain detectable not only in cell-free virions but also persist in cell-associated HIV for at least 24 months (up to 48 months for two patients).
Resistance mutations persisted in a drug-free environment in circulating and in intracellular HIV strains in five of five patients (32–36). This absence of genotypic change is supported by phylogenetic analysis of HIV DNA protease gene clones at baseline, showing the early expansion of a dominant homogenous [35–37] and resistant population. Indeed, the absence of detectable intracellular wild-type quasispecies (i.e., the absence of competition) in our PHI patients is consistent with the persistence of resistant viruses during follow-up.
This is supported by the detection of genotypic resistance in PBMC HIV DNA as soon as PHI by whole population-based sequencing methods in all 44 patients, suggesting that the cell-associated initial viral pool is mainly homogenous and resistant in those patients . Despite the usual dynamic processes affecting the pool of infected cells , HIV DNA isolated from circulating PBMC far from PHI still exhibited the same resistance mutational pattern than at the time of PHI, indicating that resistant viruses entering the cellular reservoir early in infection had not been replaced. Interestingly, phylogenetic analysis of the RT gene showed that, for some patients, HIV RNA in plasma did not cluster with paired HIV DNA extracted from circulating blood cells at the same time-point. This finding suggested that circulating virions recently produced in plasma might arise from sources other than circulating infected blood cells [40,41]. However, HIV RNA sequence sampled far from PHI still exhibited the same resistance mutational pattern as at the time of PHI, thus suggesting that other reservoirs (such as anatomical reservoirs ) had been also fuelled with the same resistant strains at the time of PHI.
Interestingly, if a high number of resistance-associated mutations within the viral genome at time of PHI makes the occurrence of back mutations at all relevant loci less likely [43,44], it would have been expected that viruses harbouring only one single mutation, such as K103N, would have reverted at a relatively early time . However, in patient 36, single mutation K103N conferring little fitness impairment [4,15,46], persisted for 24 months in both HIV RNA and archived HIV DNA without any drug selective pressure. In contrast, mutation M184V with deleterious impact on viral fitness [47,48] shifted to wild-type amino acid residue in plasma for patient 40 as soon as lamivudine-selective pressure was discontinued. Reversion of 184V acquired at the time of PHI has already been described in plasma HIV RNA [44,49]. However, even if no longer detectable in plasma, we showed that this resistance mutation persisted in the cellular reservoir, which makes rapid re-emergence possible in plasma if lamivudine was to be resumed. Moreover, in patient 7, a mixture of amino acid residue M/I was detected at position 184 of the RT gene in HIV DNA, but only wild-type amino acid residue was detected in paired plasma HIV RNA. This suggests that strains harbouring a wild-type amino acid residue at position 184 of the RT gene overwhelmed the mutated strains and were the dominant population in plasma in the absence of drug-selective pressure. Nevertheless, resistant strains harbouring M184V mutations would quickly emerge in plasma if lamivudine was to be started in patient 7.
There is evidence that transmitted drug-resistant HIV can lead to suboptimal response to first-line therapy in newly infected patients [16,19,50–52]. Intriguingly, patients 37 and 38 who harboured viral strains that were resistant to at least two drugs from their triple combination achieved undetectable plasma HIV RNA as soon as M6, which was sustained until M24 and M48, respectively. These findings suggest a T-cell mediated control of HIV replication [53–55], with a specific recognition of mutated epitopes [56–58]. Other factors such as neutralizing antibodies , specific HLA types or host genetic factors , and chemokine receptor polymorphisms might have played a role. Of note, we cannot exclude that these two patients would have achieved undetectable plasma viral load even without any therapeutic intervention. Indeed, plasma viral load had been spontaneously below 400 copies/ml without any antiretroviral treatment between the M6 and M24 following seroconversion in 4% of patients included in the Seroco study [61,62].
Three out of five treated patients had a slow decrease in HIV RNA, with a prolonged viral replication under drug selective pressure, thus promoting the accumulation and storage of additional drug-resistance mutations selected by the ongoing treatment in two patients, and jeopardizing the already limited therapeutic options . Moreover, persisting viral replication despite HAART might increase secondary sexual transmission of drug-resistant variants [17,64].
In conclusion, transmitted HIV resistant strains ensure the dissemination and establishment of the cellular reservoir at the earliest time-point in HIV infection, with the same transmitted resistant strain. They are durably detectable in blood plasma and are archived in PBMC for lengthy periods of time. At the time patients 32–41 were included in the Primo Cohort, French guidelines recommended performing restrospective genotypic resistance test for an epidemiological purpose in patients with PHI . In this context, classical empirical antiretroviral triple-combination might be suboptimal. Our results strengthen the accuracy of recent 2004 French guidelines which recommend performing genotypic resistance tests prospectively in patients with PHI , with results available soon after PHI confirmation. Thus, treatment failures such as occurred in patients 39–41 would not be expected to occur with current practice guidelines in use, as if early HAART is initiated at the time of PHI, its virologic efficacy would be closely monitored to allow a rapid modification of antiretroviral regimen if resistance mutations were detected, in order not to impair the already limited therapeutic options.
We thank all the patients for their participation in this study. We also thank F. Letourneur, E. Abachin and the Scientific Committee of the PRIMO Cohort for continuous helpful discussions.
Sponsorship: This work was supported by grants from ANRS (Agence Nationale de Recherche sur le Sida), and by a scholarship (J. Ghosn) from Sidaction-Ensemble Contre le Sida.
1. Tamalet C, Fantini J, Tourres C, Yahi N. Resistance of HIV-1
to multiple antiretroviral drugs in France: a 6-year survey (1997–2002) based on an analysis of over 7000 genotypes. AIDS 2003; 17:2383–2388.
2. Richman D, Morton S, Wrin T, Hellmann N, Berry S, Shapiro M, et al
. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18:1393–1401.
3. Sabin CA, Hill T, Lampe F, Matthias R, Bhagani S, Gilson R, et al
. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ 2005; 330:695.
4. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al
. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472–480.
5. Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol 2000; 74:6262–6268.
6. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999; 73:3744–3752.
7. Yerly S, Jost S, Telenti A, Flepp M, Kaiser L, Chave JP, et al
. Infrequent transmission of HIV-1
drug-resistant variants. Antiviral Ther 2004; 9:375–384.
8. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, et al
. Sexual transmission of an HIV-1
variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998; 339:307–311.
9. Colson P, Ravaux I, Yahi N, Tourres C, Gallais H, Tamalet C. Transmission of HIV-1
variants resistant to the three classes of antiretroviral agents: implications for HIV therapy in primary infection
. AIDS 2002; 16:507–509.
10. Taylor S, Cane P, Hue S, Xu L, Wrin T, Lie Y, et al
. Identification of a transmission chain of HIV type 1 containing drug resistance-associated mutations. AIDS Res Hum Retroviruses 2003; 19:353–361.
11. Descamps D, Chaix ML, Andre P, Brodard V, Cottalorda J, Deveau C, et al
. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection
and in antiretroviral-naive chronically infected patients in 2001–2002. J Acquir Immune Defic Syndr 2005; 38:545–552.
12. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1
drug resistance mutations
after stopping therapy. AIDS 1999; 13:F123–F127.
13. Delaugerre C, Valantin MA, Mouroux M, Bonmarchand M, Carcelain G, Duvivier C, et al
. Re-occurrence of HIV-1
drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS 2001; 15:2189–2191.
14. Chan KC, Galli RA, Montaner JS, Harrigan PR. Prolonged retention of drug resistance mutations
and rapid disease progression in the absence of therapy after primary HIV infection. AIDS 2003; 17:1256–1258.
15. Little SJ, Koelsch KK, Ignacio CC, Wong JK, Frost SD, Richman D. Persistence of transmitted drug resistant virus among subjects with primary HIV infection deferring antiretroviral therapy.Eleventh Conference on Retroviruses and Opportunistic Infections
. San Francisco, February 2004 [abstract 36LB].
16. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al
. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385–394.
17. Brenner B, Routy JP, Quan Y, Moisi D, Oliveira M, Turner D, et al
of multidrug-resistant HIV-1
in primary infection
leading to superinfection. AIDS 2004; 18:1653–1660.
18. Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, et al
of primary drug resistance among recently HIV-1
infected adults. AIDS 2004; 18:1683–1689.
19. Harzic M, Pellegrin I, Deveau C, Chaix ML, Dubeaux B, Garrigue I, et al
. Genotypic drug resistance during HIV-1 primary infection
in France (1996–1999): frequency and response to treatment. AIDS 2002; 16:793–796.
20. Markowitz M, Mohri H, Mehandru S, Shet A, Berry L, Kalyanaraman R, et al
. Infection with multidrug resistant, dual-tropic HIV-1
and rapid progression to AIDS: a case report. Lancet 2005; 365:1031–1038.
21. Bhaskaran K, Pillay D, Walker AS, Fisher M, Hawkins D, Gilson R, et al
. Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters. AIDS 2004; 18:1471–1473.
22. Chaix ML, Descamps D, Harzic M, Schneider V, Deveau C, Tamalet C, et al
. Stable prevalence of genotypic drug resistance mutations
but increase in non-B virus among patients with primary HIV-1
infection in France. AIDS 2003; 17:2635–2643.
23. Schiffer V, Deveau C, Meyer L, Iraqui I, Nguyen-Wartel A, Chaix ML, et al
. Recent changes in the management of primary HIV-1
infection: results from the French PRIMO cohort. HIV Medicine 2004; 5:326–333.
24. Desquilbet L, Goujard C, Rouzioux C, Sinet M, Deveau C, Chaix ML, et al
. Does transient HAART during primary HIV-1
infection lower the virological set-point? AIDS 2004; 18:2361–2369.
25. Delfraissy JF. Prise en charge thérapeutique des personnes infectées par le VIH.
Médecine-Sciences Flammarion ed. Paris; 2004.
26. Delfraissy JF. Prise en charge thérapeutique des personnes infectées par le VIH.
Médecine-Sciences Flammarion ed. Paris; 1999.
27. Hoen B, Fournier I, Charreau I, Lacabaratz-Porret C, Burgard M, Arvieux C, et al
. Structured treatment interruptions in primary HIV infection: final results of the multicenter prospective Primstop pilot trial.Eleventh Conference on Retroviruses and Opportunistic Infections
. San Francisco, February 2004 [abstract 395].
28. Emilie D, Burgard M, Lascoux-Combe C, Laughlin M, Krzysiek R, Pignon C, et al
. Early control of HIV replication in primary HIV-1
infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study. AIDS 2001; 15:1435–1437.
29. Goujard C, Marcellin F, Chavez H, Meiffredy V, Rouzioux C, Venet A, et al
. HIV immune and virological responses following the administration of IL-2 either alone or combined to ALVAC-HIV 1433 and HIV lipopeptides in patients treated early with HAART during primary infection: the ANRS 095 randomized study.Eleventh Conference on Retroviruses and Opportunistic Infections
. San Francisco, February 2004 [abstract 285].
30. Rouet F, Ekouevi DK, Chaix ML, Burgard M, Inwoley A, Tony TD, et al
. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 2005; 43:2709–2717.
31. Rouzioux C, Hubert JB, Burgard M, Deveau C, Goujard C, Bary M, et al
. Early Levels of HIV-1
DNA in Peripheral Blood Mononuclear Cells Are Predictive of Disease Progression Independently of HIV-1
RNA Levels and CD4+ T Cell Counts. J Infect Dis 2005; 192:46–55.
32. Kostrikis LG, Touloumi G, Karanicolas R, Pantazis N, Anastassopoulou C, Karafoulidou A, et al
. Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J Virol 2002; 76:10099–10108.
33. Pasquier C, Millot N, Njouom R, Sandres K, Cazabat M, Puel J, et al
subtyping using phylogenetic analysis of pol gene sequences. J Virol Methods 2001; 94:45–54.
34. Felsenstein J. PHYLIP, Phylogeny Inference Package, version 3.6 (alpha).
In. Seattle: Department of genetics, University of Washington; 2001.
35. Sagar M, Lavreys L, Baeten JM, Richardson BA, Mandaliya K, Chohan BH, et al
. Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol 2003; 77:12921–12926.
36. Delwart E, Magierowska M, Royz M, Foley B, Peddada L, Smith R, et al
. Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection
. AIDS 2002; 16:189–195.
37. Palmer S, Kearney M, Maldarelli F, Kottilil S, Lucey D, Metcaf J, et al
. Genetics of HIV-1
populations in acute and chronic infection. Antivir Ther 2002; 7:S43.
38. Gunthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses 1998; 14:869–876.
39. Strain MC, Gunthard HF, Havlir DV, Ignacio CC, Smith DM, Leigh-Brown AJ, et al
. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence
. Proc Natl Acad Sci U S A 2003; 100:4819–4824.
40. Lambotte O, Chaix ML, Gubler B, Nasreddine N, Wallon C, Goujard C, et al
. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 2004; 18:1147–1158.
41. Chun TW, Davey RT Jr, Ostrowski M, Shawn Justement J, Engel D, Mullins JI, et al
. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 2000; 6:757–761.
42. Smith DM, Wong JK, Mai HT, Moreno JM, Russell TM, Ignacio CC, et al
. Slow reversion of HIV transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors in semen. Antivir Ther 2005; 10:S128.
43. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, et al
and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection
. J Virol 2002; 76:1753–1761.
44. Gandhi RT, Wurcel A, Rosenberg ES, Johnston MN, Hellmann N, Bates M, et al
. Progressive reversion of human immunodeficiency virus type 1 resistance mutations
in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 2003; 37:1693–1698.
45. Wirden M, Delaugerre C, Marcelin AG, Ktorza N, Ait Mohand H, Dominguez S, et al
. Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy. Antimicrob Agents Chemother 2004; 48:644–647.
46. Capetti AF, Gabris AI, Drago L, Vigevani GM. Can a K103N HIV strain stably overcome the wild type in the absence of non-nucleoside reverse transcriptase inhibitor selective pressure? AIDS 2005; 19:633–634.
47. Wei X, Liang C, Gotte M, Wainberg MA. Negative effect of the M184V mutation in HIV-1
reverse transcriptase on initiation of viral DNA synthesis. Virology 2003; 311:202–212.
48. Turner D, Brenner B, Routy JP, Moisi D, Rosberger Z, Roger M, et al
. Diminished representation of HIV-1
variants containing select drug resistance-conferring mutations in primary HIV-1
infection. J Acquir Immune Defic Syndr 2004; 37:1627–1631.
49. Delaugerre C, Morand-Joubert L, Chaix ML, Picard O, Marcelin AG, Schneider V, et al
of multidrug-resistant HIV-1
without antiretroviral treatment 2 years after sexual transmission. Antivir Ther 2004; 9:415–421.
50. Tang JW, Pillay D. Transmission of HIV-1
drug resistance. J Clin Virol 2004; 30:1–10.
51. Chaix ML, Desquilbet L, Cottalorda J, Descamps D, Deveau C, Galimand J, et al
. Sub-optimal response to HAART in patients treated at time of primary HIV-1
infection and infected with HIV resistant strains. Antivir Ther 2005; 10:S127.
52. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al
. Time trends in primary HIV-1
drug resistance among recently infected persons. JAMA 2002; 288:181–188.
53. Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA, et al
. Early highly active antiretroviral therapy for acute HIV-1
infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000; 97:3382–3387.
54. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al
. Immune control of HIV-1
after early treatment of acute infection. Nature 2000; 407:523–526.
55. Lacabaratz-Porret C, Urrutia A, Doisne JM, Goujard C, Deveau C, Dalod M, et al
. Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J Infect Dis 2003; 187:748–757.
56. Samri A, Haas G, Duntze J, Bouley JM, Calvez V, Katlama C, et al
. Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. J Virol 2000; 74:9306–9312.
57. Samri A, Jeannin P, Marcelin AG, Costagliola D, Alatrakchi N, Biligui A, et al
. CD8 T cell recognition of HIV-1
RT mutations induced by therapy with RT inhibitors in HIV-infected patients with persistent low viral load. Antivir Ther 2004; 9:S73.
58. Alatrakchi N, Duvivier C, Costagliola D, Samri A, Marcelin A, Kamkamidze G, et al
. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. AIDS 2005; 19:25–33.
59. Ngo-Giang-Huong N, Candotti D, Goubar A, Autran B, Maynart M, Sicard D, et al
. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res Hum Retroviruses 2001; 17:1435–1446.
60. Katzenstein TL, Eugen-Olsen J, Hofmann B, Benfield T, Pedersen C, Iversen AK, et al
. HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:10–14.
61. Madec Y, Boufassa F, Rouzioux C, Delfraissy JF, Meyer L. Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon? Clin Infect Dis 2005; 40:1350–1354.
62. Hubert JB, Burgard M, Dussaix E, Tamalet C, Deveau C, Le Chenadec J, et al
. Natural history of serum HIV-1
RNA levels in 330 patients with a known date of infection. The SEROCO Study Group. AIDS 2000; 14:123–131.
63. Kantor R, Shafer RW, Follansbee S, Taylor J, Shilane D, Hurley L, et al
. Evolution of resistance to drugs in HIV-1
-infected patients failing antiretroviral therapy. AIDS 2004; 18:1503–1511.
PRIMO Cohort Scientific Committe
M.-L. Chaix (Laboratoire de Virologie, EA MRT 36 20, Université Paris V, CHU Necker-Enfants Malades, Paris, France); J.-F. Delfraissy (CHU de Bicêtre, INSERM E 109 Université Paris XI, Le Kremlin-Bicêtre, France); C. Deveau (INSERM U569, Université Paris XI, Le Kremlin-Bicêtre, France); I. Garrigue (Laboratoire de Virologie, CHU Pellegrin, Bordeaux, France); C. Goujard (CHU de Bicêtre, Inserm E109 Université Paris XI, Le Kremlin-Bicêtre, France); M. Harzic (Laboratoire de Virologie, Hôpital Le Chesnay, Versailles, France); L. Meyer (INSERM U569, Université Paris XI, Le Kremlin-Bicêtre, France); I. Pellegrin (Laboratoire de Virologie, CHU Pellegrin, Bordeaux, France); C. Rouzioux (Laboratoire de Virologie, EA MRT 36 20, Université Paris V, CHU Necker-Enfants Malades, Paris, France); M. Sinet (INSERM E 0109 Université Paris XI, Le Kremlin-Bicêtre, France); A. Venet (INSERM E 0109 Université Paris XI, Le Kremlin-Bicêtre, France).
PRIMO Cohort Study Group
J. Beylot, P. Morlat, D. Malvy, M. Bonarek, F. Bonnet (St André Bordeaux); C. Caulin, E. Badsi, J. Cervoni, V. Vincent (Lariboisière Paris); J.M. Molina, D. Ponscarme (St Louis Paris); A.P. Blanc, T. Allègre (Aix en Provence); J.F. Delfraissy, C. Goujard, Y. Quertainmont (Bicêtre Le Kremlin Bicêtre); F. Raffi, V. Reliquet, E. Billaud, J.L. Esnault (Hôtel-Dieu Nantes); F. Bricaire, C. Katlama, H. Ait Mohand, C. Duvivier, J. Ghosn (Pitié-Salpétrière PARIS); E. Rouveix, S. Morelon, C. Dupont (A. Paré Boulogne); J. Reynes, V. Baillat, V. Lemoing (Montpellier); J.M. Livrozet, F. Jeanblanc, P. Chiarello (E. Herriot Lyon); R. Thomas, F. Souala, C. Bouvier (Pontchaillou Rennes); A. Cabié, S. Abel (Fort de France); J.L. Vildé, C. Jestin, C. Jadand (Bichat Paris); E. Pichard, P. Fialaire, J.M. Chennebault (Angers); P. Henon, G. Beck-Wirth, C. Beck (Emile Muller Mulhouse); D. Sereni, C. Lascoux (St Louis Paris); S. Herson, A. Simon (Pitié-Salpétrière Paris); B. Dupont, J.P. Viard (Necker Paris); A. Devidas, P. Chevojon, P. Kousignian (Corbeil); P. Massip, M. Obadia (Purpan Toulouse); J. Beytout, C. Jacomet (Hôtel Dieu Clermont-Ferrand); H. Aumaître, B. Delmas, M. Saada (Joffre Perpignan); P. Yeni, E. Bouvet, I. Fournier, P. Campa, S. Abgrall (Bichat Paris); A. Sobel, P. Lesprit, A.S. Lascaux (H. Mondor Créteil); H. Gallais, I. Ravaux, C. Tomei (La Conception Marseille); R. Verdon, M. Six (Caen); C. Trepo, C. Augustin-Normand (Hôtel-Dieu Lyon); G. Pialoux, W. Rozenbaum, L. Slama, P. Mariot (Tenon Paris); P. Morel, F. Timsit (St Louis Paris); B. Hoen, C. Drobacheff (St Jacques Besançon); M. Kazatchkine, P. Castiel, D. Batisse (HEGP Paris); D. Sicard, D. Salmon, A. Brunet (Cochin Paris); P. Galanaud, F. Boué, J. Polo de Veto (A. Béclère Clamart); P. Veyssier, D. Merrien (Compiegne); P.M. Girard, D. Samanon-Bollens (St Antoine Paris); M. Bentata, F. Rouges (Avicenne Bobigny); J.P. Cassuto, C. Sohn, E. Rosenthal (L'Archet Nice); P. Dellamonica, S. Chaillou (L'Archet Nice); J.M. Ragnaud, I. Raymond (Pellegrin Bordeaux); P. Choutet, P. Nau, F. Bastides (Tours); P. Canton, L. Boyer (Nancy); Y. Mouton, A. Dos Santos (Tourcoing); P. Chavanet, M. Buisson (Dijon); G. Dien, C. Daniel, C. Devaurs (St-Brieuc); Y. Redelsperger, B. Ponge, L. Fournier (Melun); J. Laffay, A. Greder Belan (A. Mignot Le Chesnay); I. Lamaury, A. Cheret (Pointe a Pitre); M. Gayraud, L. Bodard (IMM Jourdan Paris); J.C. Imbert, O. Picard (St Antoine Paris); E. Oksenhendler, L. Gérard (St Louis Paris); G. Huchon, A. Compagnucci (Hôtel-Dieu Paris); P. Lagarde, F. David (Lagny); Ph. Vinceneux, M. Bloch (L. Mourier Colombes); B. Audhuy, N. Plaisance (Colmar); O. Bletry, D. Zucman (Foch Suresnes); L. Bernard, J. Salomon (R. Poincaré Garches); M. Chousterman, V. Garray (Intercommunal Creteil); A. Regnier (Vichy); M. Uzan, F. Saint-Dizier (Ducuing Toulouse); J.J Girard (Loches); P. Moreau, O. Vaillant (Lorient); F. Grihon (Noyon); A. Lepretre (Eaubonne); D. Houlbert (Alençon); F. Caron, Y. Debab (Rouen); F.Trémolières, V. Perronne (Mantes La Jolie); A. Lepeu, B. Slama (Avignon); E. Brottier, L. Faba (La Rochelle); C. Miodovski (Paris); R. Armero, E. Counillon (Frejus); G. Guermonprez, A. Dulioust (Bris s/Forges); P. Boudon, D. Malbec (Aulnay s/Bois); O. Patey, C. Semaille (Villeneuve St Georges); J. Deville, G. Remy, I. Beguinot (Reims); G. Gonzalez, F. Sanlaville (Sens).
64. Leigh Brown AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, Daar ES, et al
. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003; 187:683–686.